Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease

Neurodegenerative Diseases

Volumn 8, Issue 6, 2011, Pages 397-412

  Hinault, Marie Pierre ^a   Farina Henriquez Cuendet, America ^a   Goloubinoff, Pierre ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Synuclein; Aggresome; Autophagy; Molecular chaperones; Parkinson's disease; Proteasome

Indexed keywords

4 PHENYLBUTYRIC ACID; ALPHA SYNUCLEIN; CHAPERONE; DJ 1 PROTEIN; HOLDASE; HYDROQUININE; PROTEASOME; PROTEINASE; TETRAHYDROQUINOLINONE; UNCLASSIFIED DRUG; UNFOLDASE;

AGGRESOME; AGING; AUTOPHAGY; CELL AGING; CELL MIGRATION; DRUG MECHANISM; HUMAN; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; REVIEW; UPREGULATION;

ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; AUTOPHAGY; CELLS; HUMANS; MOLECULAR CHAPERONES; PARKINSON DISEASE; PEPTIDE HYDROLASES;

EID: 79960562137     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000324514     Document Type: Review

References (182)

1. Fitzgerald JC, Plun-Favreau H: Emerging pathways in genetic Parkinsons disease: autosomal- recessive genes in Parkinsons disease - a common pathway? FEBS J 2008; 275: 5758-5766.
2. Gasser T: Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009; 11:e22.
3. Hindle JV: Ageing, neurodegeneration and Parkinsons disease. Age Ageing 2010; 39: 156-161.
4. Richardson JR, Shalat SL, Buckley B, Winnik B, OSuilleabhain P, Diaz-Arrastia R, Reisch J, German DC: Elevated serum pesticide levels and risk of Parkinson disease. Arch Neurol 2009; 66: 870-875.
5. Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, Lee VM, Trojanowski JQ, Smith DH: Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol 2007; 208: 185-192. (Pubitemid 350101496)
6. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM: Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008; 28: 7687-7698.
7. Henchcliffe C, Beal MF: Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008; 4: 600-609.
8. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, Trojanowski JQ, Lee VM: Mouse model of multiple system atrophy alpha- synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005; 45: 847-859. (Pubitemid 40395264)
9. Dauer W, Przedborski S: Parkinsons disease: mechanisms and models. Neuron 2003; 39: 889-909.
10. Cookson MR: The biochemistry of Parkinsons disease. Annu Rev Biochem 2005; 74: 29-52.
11. Shibasaki Y, Baillie DA, St Clair D, Brookes AJ: High-resolution mapping of SNCA encoding alpha-synuclein, the non-A beta component of Alzheimers disease amyloid precursor, to human chromosome 4q21.3-q22 by fluorescence in situ hybridization. Cytogenet Cell Genet 1995; 71: 54-55.
12. Lavedan C: The synuclein family. Genome Res 1998; 8: 871-880. (Pubitemid 28495441)
13. Kahle PJ, Neumann M, Ozmen L, Haass C: Physiology and pathophysiology of alphasynuclein: cell culture and transgenic animal models based on a Parkinsons diseaseassociated protein. Ann NY Acad Sci 2000; 920: 33-41. (Pubitemid 32056549)
14. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM: Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 2000; 20: 3214-3220. (Pubitemid 30263139)
15. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H: NACP/alphasynuclein- positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinsons disease brains. Acta Neuropathol 2000; 99: 14-20. (Pubitemid 30093433)
16. Tofaris GK, Spillantini MG: Physiological and pathological properties of alphasynuclein. Cell Mol Life Sci 2007; 64: 2194-2201.
17. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC: Alphasynuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005; 123: 383-396. (Pubitemid 41546670)
18. Volles MJ, Lansbury PT Jr: Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinsons disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002; 41: 4595-4602. (Pubitemid 34275660)
19. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr: Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002; 418: 291. (Pubitemid 34790672)
20. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr: Alphasynuclein, especially the Parkinsons disease- associated mutants, forms porelike annular and tubular protofibrils. J Mol Biol 2002; 322: 1089-1102. (Pubitemid 35266514)
21. Lashuel HA, Lansbury PT Jr: Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 2006; 39: 167-201. (Pubitemid 44711851)
22. Hinault MP, Cuendet AF, Mattoo RU, Mensi M, Dietler G, Lashuel HA, Goloubinoff P: Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain cochaperones. J Biol Chem 2010; 285: 38173-38182.
23. Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ: The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 2005; 280: 23727-23734. (Pubitemid 40884855)
24. Koga H, Kaushik S, Cuervo AM: Protein homeostasis and aging: the importance of exquisite quality control. Ageing Res Rev 2010, E-pub ahead of print.
25. Hartl FU, Hayer-Hartl M: Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002; 295: 1852-1858. (Pubitemid 34214115)
26. Hinault MP, Ben-Zvi A, Goloubinoff P: Chaperones and proteases: cellular fold-controlling factors of proteins in neurodegenerative diseases and aging. J Mol Neurosci 2006; 30: 249-265. (Pubitemid 46568344)
27. Meriin AB, Sherman MY: Role of molecular chaperones in neurodegenerative disorders. Int J Hyperthermia 2005; 21: 403-419. (Pubitemid 41102940)
28. Brown IR: Heat shock proteins and protection of the nervous system. Ann NY Acad Sci 2007; 1113: 147-158. (Pubitemid 350015026)
29. Luo GR, Chen S, Le WD: Are heat shock proteins therapeutic target for Parkinsons disease? Int J Biol Sci 2007; 3: 20-26. (Pubitemid 46155761)
30. Adachi H, Katsuno M, Waza M, Minamiyama M, Tanaka F, Sobue G: Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications. Int J Hyperthermia 2009; 25: 647-654.
31. Goloubinoff P, Christeller JT, Gatenby AA, Lorimer GH: Reconstitution of active dimeric ribulose bisphosphate carboxylase from an unfolded state depends on two chaperonin proteins and Mg-ATP. Nature 1989; 342: 884-889. (Pubitemid 20021332)
32. Buchner J, Schmidt M, Fuchs M, Jaenicke R, Rudolph R, Schmid FX, Kiefhaber T: GroE facilitates refolding of citrate synthase by suppressing aggregation. Biochemistry 1991; 30: 1586-1591.
33. Veinger L, Diamant S, Buchner J, Goloubinoff P: The small heat-shock protein IbpB from Escherichia coli stabilizes stress-denatured proteins for subsequent refolding by a multichaperone network. J Biol Chem 1998; 273: 11032-11037. (Pubitemid 28204946)
34. Van Montfort R, Slingsby C, Vierling E: Structure and function of the small heat shock protein/alpha-crystallin family of molecular chaperones. Adv Protein Chem 2001; 59: 105-156. (Pubitemid 34169303)
35. Rudiger S, Germeroth L, Schneider-Mergener J, Bukau B: Substrate specificity of the DnaK chaperone determined by screening cellulose-bound peptide libraries. Embo J 1997; 16: 1501-1507. (Pubitemid 27151945)
36. Sharma SK, Christen P, Goloubinoff P: Disaggregating chaperones: an unfolding story. Curr Protein Pept Sci 2009; 10: 432-446.
37. Finka A, Mattoo RU, Goloubinoff P: Metaanalysis of heat-and chemically upregulated chaperone genes in plant and human cells. Cell Stress Chaperones 2011; 16: 15-31.
38. Rekas A, Adda CG, Andrew Aquilina J, Barnham KJ, Sunde M, Galatis D, Williamson NA, Masters CL, Anders RF, Robinson CV, Cappai R, Carver JA: Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J Mol Biol 2004; 340: 1167-1183. (Pubitemid 38968709)
39. Zourlidou A, Payne Smith MD, Latchman DS: HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. J Neurochem 2004; 88: 1439-1448. (Pubitemid 38366920)
40. Kitao Y, Matsuyama T, Takano K, Tabata Y, Yoshimoto T, Momoi T, Yamatodani A, Ogawa S, Hori O: Does ORP150/HSP12A protect dopaminergic neurons against MPTP/ MPP(+)-induced neurotoxicity? Antioxid Redox Signal 2007; 9: 589-595. (Pubitemid 46598256)
41. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259. (Pubitemid 36131051)
42. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A: DJ-1 is a redoxdependent molecular chaperone that inhibits alphasynuclein aggregate formation. PLoS Biol 2004; 2:e362.
43. Inden M, Taira T, Kitamura Y, Yanagida T, Tsuchiya D, Takata K, Yanagisawa D, Nishimura K, Taniguchi T, Kiso Y, Yoshimoto K, Agatsuma T, Koide-Yoshida S, Iguchi- Ariga SM, Shimohama S, Ariga H: PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinsons disease rat model. Neurobiol Dis 2006; 24: 144-158. (Pubitemid 44416214)
44. Liu F, Nguyen JL, Hulleman JD, Li L, Rochet JC: Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinsons disease. J Neurochem 2008; 105: 2435-2453. (Pubitemid 351782273)
45. Johnston JA, Ward CL, Kopito RR: Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998; 143: 1883-1898. (Pubitemid 29022611)
46. Garcia-Mata R, Bebok Z, Sorscher EJ, Sztul ES: Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol 1999; 146: 1239-1254. (Pubitemid 29477692)
47. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM: Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinsons disease. Science 2002; 295: 865-868. (Pubitemid 34118369)
48. Dong Z, Wolfer DP, Lipp HP, Bueler H: Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther 2005; 11: 80-88. (Pubitemid 40012001)
49. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ: Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 2004; 279: 25497-25502. (Pubitemid 38756808)
50. Huang C, Cheng H, Hao S, Zhou H, Zhang X, Gao J, Sun QH, Hu H, Wang CC: Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates. J Mol Biol 2006; 364: 323-336. (Pubitemid 44717537)
51. Dedmon MM, Christodoulou J, Wilson MR, Dobson CM: Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem 2005; 280: 14733-14740. (Pubitemid 40562821)
52. Durrenberger PF, Filiou MD, Moran LB, Michael GJ, Novoselov S, Cheetham ME, Clark P, Pearce RK, Graeber MB: DnaJB6 is present in the core of Lewy bodies and is highly upregulated in parkinsonian astrocytes. J Neurosci Res 2009; 87: 238-245.
53. Hageman J, Rujano MA, van Waarde MA, Kakkar V, Dirks RP, Govorukhina N, Oosterveld-Hut HM, Lubsen NH, Kampinga HH: A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol Cell 2010; 37: 355-369.
54. Falsone SF, Kungl AJ, Rek A, Cappai R, Zangger K: The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha- synuclein. J Biol Chem 2009; 284: 31190-31199.
55. Kong B, Chae Y, Lee K: Degradation of wildtype alpha-synuclein by a molecular chaperone leads to reduced aggregate formation. Cell Biochem Funct 2005; 23: 125-132. (Pubitemid 40363684)
56. Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P: Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 2008; 118: 3087-3097.
57. Glover JR, Lindquist S: Hsp104, Hsp70, and Hsp40:a novel chaperone system that rescues previously aggregated proteins. Cell 1998; 94: 73-82. (Pubitemid 28347471)
58. Goloubinoff P, Mogk A, Zvi AP, Tomoyasu T, Bukau B: Sequential mechanism of solubilization and refolding of stable protein aggregates by a bichaperone network. Proc Natl Acad Sci USA 1999; 96: 13732-13737.
59. Schuermann JP, Jiang J, Cuellar J, Llorca O, Wang L, Gimenez LE, Jin S, Taylor AB, Demeler B, Morano KA, Hart PJ, Valpuesta JM, Lafer EM, Sousa R: Structure of the Hsp110:Hsc70 nucleotide exchange machine. Mol Cell 2008; 31: 232-243.
60. Shorter J, Lindquist S: Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell 2006; 23: 425-438. (Pubitemid 44128844)
61. Diamant S, Ben-Zvi AP, Bukau B, Goloubinoff P: Size-dependent disaggregation of stable protein aggregates by the DnaK chaperone machinery. J Biol Chem 2000; 275: 21107-21113. (Pubitemid 30481803)
62. Ben-Zvi A, De Los Rios P, Dietler G, Goloubinoff P: Active solubilization and refolding of stable protein aggregates by cooperative unfolding action of individual hsp70 chaperones. J Biol Chem 2004; 279: 37298-37303. (Pubitemid 39195436)
63. Goloubinoff P, De Los Rios P: The mechanism of Hsp70 chaperones: (entropic) pulling the models together. Trends Biochem Sci 2007; 32: 372-380. (Pubitemid 47126861)
64. Arias E, Cuervo AM: Chaperone-mediated autophagy in protein quality control. Curr Opin Cell Biol 2010, E-pub ahead of print.
65. Nardai G, Csermely P, Soti C: Chaperone function and chaperone overload in the aged: a preliminary analysis. Exp Gerontol 2002; 37: 1257-1262. (Pubitemid 35418284)
66. Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB: Gene expression profiling of sporadic Parkinsons disease substantia nigra pars compacta reveals impairment of ubiquitinproteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann NY Acad Sci 2005; 1053: 356-375. (Pubitemid 43031116)
67. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH: Alterations in lysosomal and proteasomal markers in Parkinsons disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009; 35: 385-398.
68. Jin J, Hulette C, Wang Y, Zhang T, Pan C, Wadhwa R, Zhang J: Proteomic identification of a stress protein, mortalin/mthsp70/ GRP75:relevance to Parkinson disease. Mol Cell Proteomics 2006; 5: 1193-1204. (Pubitemid 44103391)
69. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, Graeber MB: Whole genome expression profiling of the medial and lateral substantia nigra in Parkinsons disease. Neurogenetics 2006; 7: 1-11. (Pubitemid 43327678)
70. Bernasconi R, Molinari M: ERAD and ERAD tuning: disposal of cargo and of ERAD regulators from the mammalian ER. Curr Opin Cell Biol 2010, E-pub ahead of print.
71. Jung T, Catalgol B, Grune T: The proteasomal system. Mol Aspects Med 2009; 30: 191-296.
72. Dembla-Rajpal N, Seipelt R, Wang Q, Rymond BC: Proteasome inhibition alters the transcription of multiple yeast genes. Biochim Biophys Acta 2004; 1680: 34-45. (Pubitemid 39286740)
73. Kahn NW, Rea SL, Moyle S, Kell A, Johnson TE: Proteasomal dysfunction activates the transcription factor SKN-1 and produces a selective oxidative-stress response in Caenorhabditis elegans . Biochem J 2008; 409: 205-213.
74. Borissenko L, Groll M: Diversity of proteasomal missions: fine tuning of the immune response. Biol Chem 2007; 388: 947-955. (Pubitemid 47258534)
75. Rideout HJ, Larsen KE, Sulzer D, Stefanis L: Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 2001; 78: 899-908. (Pubitemid 32777990)
76. Rideout HJ, Lang-Rollin IC, Savalle M, Stefanis L: Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem 2005; 93: 1304-1313. (Pubitemid 40776583)
77. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC: Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003; 278: 25009-25013. (Pubitemid 37548663)
78. Ancolio K, Alves da Costa C, Ueda K, Checler F: Alpha-synuclein and the Parkinsons disease-related mutant Ala53Thr-alphasynuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci Lett 2000; 285: 79-82. (Pubitemid 30227624)
79. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM, Ischiropoulos H: Induction of alphasynuclein aggregation by intracellular nitrative insult. J Neurosci 2001; 21: 8053-8061. (Pubitemid 32952762)
80. Machiya Y, Hara S, Arawaka S, Fukushima S, Sato H, Sakamoto M, Koyama S, Kato T: Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem 2010; 285: 40732-40744.
81. Verhoef LG, Lindsten K, Masucci MG, Dantuma NP: Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 2002; 11: 2689-2700.
82. Rubinsztein DC: The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443: 780-786. (Pubitemid 44622682)
83. Zhang NY, Tang Z, Liu CW: alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J Biol Chem 2008; 283: 20288-20298.
84. Sneppen K, Lizana L, Jensen MH, Pigolotti S, Otzen D: Modeling proteasome dynamics in Parkinsons disease. Phys Biol 2009; 6: 036005.
85. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW: Altered proteasomal function in sporadic Parkinsons disease. Exp Neurol 2003; 179: 38-46. (Pubitemid 36062617)
86. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG: Ubiquitination of alphasynuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003; 278: 44405-44411. (Pubitemid 37377190)
87. Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, Pearce RK, Graeber MB: Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinsons disease. Neurogenetics 2006; 7: 139-148. (Pubitemid 44078291)
88. Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, Breakefield XO, Hyman BT: A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol 2001; 159: 339-344. (Pubitemid 33704219)
89. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT: Torsin A and heat shock proteins act as molecular chaperones: suppression of alpha- synuclein aggregation. J Neurochem 2002; 83: 846-854. (Pubitemid 35316034)
90. Cao S, Gelwix CC, Caldwell KA, Caldwell GA: Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans . J Neurosci 2005; 25: 3801-3812. (Pubitemid 40570413)
91. Kopito RR: Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10: 524-530.
92. Opazo F, Krenz A, Heermann S, Schulz JB, Falkenburger BH: Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. J Neurochem 2008; 106: 529-540.
93. Wong ES, Tan JM, Soong WE, Hussein K, Nukina N, Dawson VL, Dawson TM, Cuervo AM, Lim KL: Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum Mol Genet 2008; 17: 2570-2582.
94. Zhao J, Ren Y, Jiang Q, Feng J: Parkin is recruited to the centrosome in response to inhibition of proteasomes. J Cell Sci 2003; 116: 4011-4019. (Pubitemid 37279315)
95. Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA: UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinsons disease. J Neurochem 2004; 90: 379-391. (Pubitemid 38938224)
96. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM: Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004; 279: 4625-4631. (Pubitemid 38199054)
97. Zaarur N, Meriin AB, Gabai VL, Sherman MY: Triggering aggresome formation: dissecting aggresome-targeting and aggregation signals in synphilin 1. J Biol Chem 2008; 283: 27575-27584.
98. Muqit MM, Davidson SM, Payne Smith MD, MacCormac LP, Kahns S, Jensen PH, Wood NW, Latchman DS: Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkins effect on neuronal survival. Hum Mol Genet 2004; 13: 117-135. (Pubitemid 38072140)
99. Diaz-Corrales FJ, Asanuma M, Miyazaki I, Miyoshi K, Ogawa N: Rotenone induces aggregation of gamma-tubulin protein and subsequent disorganization of the centrosome: relevance to formation of inclusion bodies and neurodegeneration. Neuroscience 2005; 133: 117-135. (Pubitemid 40694163)
100. Ding WX, Yin XM: Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 2008; 4: 141-150.
101. Ravikumar B, Duden R, Rubinsztein DC: Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002; 11: 1107-1117. (Pubitemid 34521091)
102. Lamark T, Johansen T: Autophagy: links with the proteasome. Curr Opin Cell Biol 2010; 22: 192-198.
103. Iwata A, Riley BE, Johnston JA, Kopito RR: HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005; 280: 40282-40292. (Pubitemid 41779165)
104. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, Di- Prospero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP: HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447: 859-863. (Pubitemid 46920134)
105. Rideout HJ, Lang-Rollin I, Stefanis L: Involvement of macroautophagy in the dissolution of neuronal inclusions. Int J Biochem Cell Biol 2004; 36: 2551-2562. (Pubitemid 39119766)
106. De Duve C, Wattiaux R: Functions of lysosomes. Annu Rev Physiol 1966; 28: 435-492.
107. Cuervo AM: Autophagy: many paths to the same end. Mol Cell Biochem 2004; 263: 55-72. (Pubitemid 39256145)
108. Levine B, Klionsky DJ: Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004; 6: 463-477. (Pubitemid 38456176)
109. Klionsky DJ: The molecular machinery of autophagy: unanswered questions. J Cell Sci 2005; 118: 7-18. (Pubitemid 40277100)
110. Massey AC, Zhang C, Cuervo AM: Chaperone- mediated autophagy in aging and disease. Curr Top Dev Biol 2006; 73: 205-235. (Pubitemid 43878134)
111. Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, Mao Z: Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 2009; 323: 124-127.
112. Todde V, Veenhuis M, van der Klei IJ: Autophagy: principles and significance in health and disease. Biochim Biophys Acta 2009; 1792: 3-13.
113. Koga H, Cuervo AM: Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiol Dis 2010, E-pub ahead of print.
114. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D: Impaired degradation of mutant alpha-synuclein by chaperone- mediated autophagy. Science 2004; 305: 1292-1295. (Pubitemid 39129234)
115. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L: Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 2008; 283: 23542-23556.
116. Yu WH, Dorado B, Figueroa HY, Wang L, Planel E, Cookson MR, Clark LN, Duff KE: Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol 2009; 175: 736-747.
117. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA: Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem 2010; 285: 13621-13629.
118. Bejarano E, Cuervo AM: Chaperone-mediated autophagy. Proc Am Thorac Soc 2010; 7: 29-39.
119. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L: Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 2009; 4:e5515.
120. Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM: Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci USA 2006; 103: 5805-5810.
121. Isidoro C, Biagioni F, Giorgi FS, Fulceri F, Paparelli A, Fornai F: The role of autophagy on the survival of dopamine neurons. Curr Top Med Chem 2009; 9: 869-879.
122. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM: Dopamine- modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008; 118: 777-788.
123. Kabuta T, Furuta A, Aoki S, Furuta K, Wada K: Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem 2008; 283: 23731-23738.
124. Sevlever D, Jiang P, Yen SH: Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008; 47: 9678-9687.
125. Morimoto RI, Cuervo AM: Protein homeostasis and aging: taking care of proteins from the cradle to the grave. J Gerontol A Biol Sci Med Sci 2009; 64: 167-170.
126. Hahn GM, Shiu EC, Auger EA: Mammalian stress proteins HSP70 and HSP28 coinduced by nicotine and either ethanol or heat. Mol Cell Biol 1991; 11: 6034-6040. (Pubitemid 21895374)
127. Vigh L, Literati PN, Horvath I, Torok Z, Balogh G, Glatz A, Kovacs E, Boros I, Ferdinandy P, Farkas B, Jaszlits L, Jednakovits A, Koranyi L, Maresca B: Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat Med 1997; 3: 1150-1154. (Pubitemid 27444460)
128. Kato K, Ito H, Kamei K, Iwamoto I: Stimulation of the stress-induced expression of stress proteins by curcumin in cultured cells and in rat tissues in vivo. Cell Stress Chaperones 1998; 3: 152-160. (Pubitemid 28434679)
129. Griffin TM, Valdez TV, Mestril R: Radicicol activates heat shock protein expression and cardioprotection in neonatal rat cardiomyocytes. Am J Physiol Heart Circ Physiol 2004; 287:H1081-H1088. (Pubitemid 39096652)
130. Kieran D, Kalmar B, Dick JR, Riddoch- Contreras J, Burnstock G, Greensmith L: Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004; 10: 402-405. (Pubitemid 38508519)
131. Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S, Gu W, Devlin JP, Silverman RB, Morimoto RI: Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 2004; 279: 56053-56060. (Pubitemid 40066613)
132. Shen HY, He JC, Wang Y, Huang QY, Chen JF: Geldanamycin induces heat shock protein and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 2005; 280: 39962-39969. (Pubitemid 41779131)
133. Wang Q, Mosser DD, Bag J: Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum Mol Genet 2005; 14: 3673-3684. (Pubitemid 41754667)
134. Westerheide SD, Morimoto RI: Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 2005; 280: 33097-33100. (Pubitemid 41397104)
135. Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G: Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med 2006; 84: 635-646. (Pubitemid 44162553)
136. Andringa G, Jongenelen CA, Halfhide L, Drukarch B: The thiol antioxidant 1,2dithiole- 3-thione stimulates the expression of heat shock protein 70 in dopaminergic PC12 cells. Neurosci Lett 2007; 416: 76-81. (Pubitemid 46428013)
137. Haap T, Triebskorn R, Kohler HR: Acute effects of diclofenac and DMSO to Daphnia magna : immobilisation and hsp70-induction. Chemosphere 2008; 73: 353-359.
138. Sloan LA, Fillmore MC, Churcher I: Smallmolecule modulation of cellular chaperones to treat protein misfolding disorders. Curr Opin Drug Discov Devel 2009; 12: 666-681.
139. Wrona IE, Gozman A, Taldone T, Chiosis G, Panek JS: Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90. J Org Chem 2010; 75: 2820-2835.
140. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC: Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine- expanded huntingtin and related proteinopathies. Cell Death Differ 2009; 16: 46-56.
141. Riedel M, Goldbaum O, Schwarz L, Schmitt S, Richter-Landsberg C: 17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy. PLoS One 2010; 5:e8753.
142. Diamant S, Eliahu N, Rosenthal D, Goloubinoff P: Chemical chaperones regulate molecular chaperones in vitro and in cells under combined salt and heat stresses. J Biol Chem 2001; 276: 39586-39591.
143. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC: Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007; 282: 5641-5652. (Pubitemid 47093730)
144. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss- Coray T, Masliah E: Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alphasynuclein models of Parkinsons and Lewy body diseases. J Neurosci 2009; 29: 13578-13588.
145. Umeda-Kameyama Y, Tsuda M, Ohkura C, Matsuo T, Namba Y, Ohuchi Y, Aigaki T: Thioredoxin suppresses Parkin-associated endothelin receptor-like receptor-induced neurotoxicity and extends longevity in Drosophila . J Biol Chem 2007; 282: 11180-11187. (Pubitemid 47100768)
146. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC: The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann NY Acad Sci 2008; 1147: 61-69.
147. Yates MS, Kensler TW: Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect 2007; 20: 109-117. (Pubitemid 46917234)
148. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S: Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinsons models. Science 2006; 313: 324-328. (Pubitemid 44480951)
149. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S: Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 2009; 41: 308-315.
150. Liu F, Hindupur J, Nguyen JL, Ruf KJ, Zhu J, Schieler JL, Bonham CC, Wood KV, Davisson VJ, Rochet JC: Methionine sulfoxide reductase A protects dopaminergic cells from Parkinsons disease-related insults. Free Radic Biol Med 2008; 45: 242-255.
151. Smith WW, Liu Z, Liang Y, Masuda N, Swing DA, Jenkins NA, Copeland NG, Troncoso JC, Pletnikov M, Dawson TM, Martin LJ, Moran TH, Lee MK, Borchelt DR, Ross CA: Synphilin-1 attenuates neuronal degeneration in the A53T alphasynuclein
152. Rao JN, Dua V, Ulmer TS: Characterization of alpha-synuclein interactions with selected aggregation-inhibiting small molecules. Biochemistry 2008; 47: 4651-4656. (Pubitemid 351555485)
153. Lendel C, Bertoncini CW, Cremades N, Waudby CA, Vendruscolo M, Dobson CM, Schenk D, Christodoulou J, Toth G: On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and Lacmoid. Biochemistry 2009; 48: 8322-8334.
154. Amer DA, Irvine GB, El-Agnaf OM: Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinsons disease and related disorders. Exp Brain Res 2006; 173: 223-233. (Pubitemid 44264886)
155. Abe K, Kobayashi N, Sode K, Ikebukuro K: Peptide ligand screening of alpha-synuclein aggregation modulators by in silico panning. BMC Bioinformatics 2007; 8: 451.
156. Ghosh JG, Houck SA, Clark JI: Interactive sequences in the molecular chaperone, human alphaB crystallin modulate the fibrillation of amyloidogenic proteins. Int J Biochem Cell Biol 2008; 40: 954-967.
157. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL: The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem 2004; 279: 26846-26857. (Pubitemid 38812518)
158. Jiang M, Porat-Shliom Y, Pei Z, Cheng Y, Xiang L, Sommers K, Li Q, Gillardon F, Hengerer B, Berlinicke C, Smith WW, Zack DJ, Poirier MA, Ross CA, Duan W: Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. J Neurochem 2010; 114: 419-429.
159. Kim J, Harada R, Kobayashi M, Kobayashi N, Sode K: The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alphasynuclein. Mol Neurodegener 2010; 5: 20.
160. Kobayashi M, Kim J, Kobayashi N, Han S, Nakamura C, Ikebukuro K, Sode K: Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. Biochem Biophys Res Commun 2006; 349: 1139-1144. (Pubitemid 44380214)
161. Teiten MH, Eifes S, Reuter S, Duvoix A, Dicato M, Diederich M: Gene expression profiling related to anti-inflammatory properties of curcumin in K562 leukemia cells. Ann NY Acad Sci 2009; 1171: 391-398.
162. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA: Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimers disease. J Pharmacol Exp Ther 2008; 326: 196-208. (Pubitemid 351872144)
163. Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA: NSAID and antioxidant prevention of Alzheimers disease: lessons from in vitro and animal models. Ann NY Acad Sci 2004; 1035: 68-84. (Pubitemid 40362327)
164. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM: Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001; 22: 993-1005. (Pubitemid 34070638)
165. Wang MS, Boddapati S, Emadi S, Sierks MR: Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinsons disease cell model. BMC Neurosci 2010; 11: 57.
166. Ono K, Yamada M: Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006; 97: 105-115.
167. Pandey N, Strider J, Nolan WC, Yan SX, Galvin JE: Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol 2008; 115: 479-489.
168. Di Giovanni S, Eleuteri S, Paleologou KE, Yin G, Zweckstetter M, Carrupt PA, Lashuel HA: Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta- amyloid and protect against amyloidinduced toxicity. J Biol Chem 2010; 285: 14941-14954.
169. Outeiro TF, Grammatopoulos TN, Altmann S, Amore A, Standaert DG, Hyman BT, Kazantsev AG: Pharmacological inhibition of PARP-1 reduces alpha-synucleinand MPP+-induced cytotoxicity in Parkinsons disease in vitro models. Biochem Biophys Res Commun 2007; 357: 596-602. (Pubitemid 46661843)
170. Kritzer JA, Hamamichi S, McCaffery JM, Santagata S, Naumann TA, Caldwell KA, Caldwell GA, Lindquist S: Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol 2009; 5: 655-663.
171. Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu F, Cao S, Hamamichi S, Hill KJ, Caldwell KA, Bell GW, Fraenkel E, Cooper AA, Caldwell GA, McCaffery JM, Rochet JC, Lindquist S: Compounds from an unbiased chemical screen reverse both ER-to- Golgi trafficking defects and mitochondrial dysfunction in Parkinsons disease models. Dis Model Mech 2010; 3: 194-208.
172. Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, Logan T, Lansbury PT Jr: Membrane-associated farnesylated UCH-L1 promotes alphasynuclein neurotoxicity and is a therapeutic target for Parkinsons disease. Proc Natl Acad Sci USA 2009; 106: 4635-4640.
173. Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S: Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007; 101: 1491-1504. (Pubitemid 46848844)
174. Ono K, Ikemoto M, Kawarabayashi T, Ikeda M, Nishinakagawa T, Hosokawa M, Shoji M, Takahashi M, Nakashima M: A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. Parkinsonism Relat Disord 2009; 15: 649-654.
175. Vigh L, Horvath I, Maresca B, Harwood JL: Can the stress protein response be controlled by membrane-lipid therapy? Trends Biochem Sci 2007; 32: 357-363. (Pubitemid 47126860)
176. Saidi Y, Finka A, Muriset M, Bromberg Z, Weiss YG, Maathuis FJ, Goloubinoff P: The heat shock response in moss plants is regulated by specific calcium-permeable channels in the plasma membrane. Plant Cell 2009; 21: 2829-2843.
177. Saidi Y, Peter M, Finka A, Cicekli C, Vigh L, Goloubinoff P: Membrane lipid composition affects plant heat sensing and modulates Ca (2+)-dependent heat shock response. Plant Signal Behav 2010; 1: 5.
178. Chung J, Nguyen AK, Henstridge DC, Holmes AG, Chan MH, Mesa JL, Lancaster GI, Southgate RJ, Bruce CR, Duffy SJ, Horvath I, Mestril R, Watt MJ, Hooper PL, Kingwell BA, Vigh L, Hevener A, Febbraio MA: HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci USA 2008; 105: 1739-1744. (Pubitemid 351346584)
179. Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, Greensmith L: Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem 2008; 107: 339-350.
180. Weiss YG, Bromberg Z, Raj N, Raphael J, Goloubinoff P, Ben-Neriah Y, Deutschman CS: Enhanced heat shock protein 70 expression alters proteasomal degradation of IkappaB kinase in experimental acute respiratory distress syndrome. Crit Care Med 2007; 35: 2128-2138. (Pubitemid 47326450)
181. Sharma SK, De los Rios P, Christen P, Lustig A, Goloubinoff P: The kinetic parameters and energy cost of the Hsp70 chaperone as a polypeptide unfoldase. Nat Chem Biol 2010; 6: 914-920.
182. Balch WE, Morimoto RI, Dillin A, Kelly JW: Adapting proteostasis for disease intervention. Science 2008; 319: 916-919. (Pubitemid 351263754)